Employees of Sequenom gather to celebrate the one-year anniversary of the commercial launch of MaterniT21 Plus, a prenatal blood test to detect fetal chromosome abnormalities. A chalk art timeline by artist Pako Pablos depicts major milestones since Sequenom launched the genetic test one year ago.

Employees of Sequenom gather to celebrate the one-year anniversary of the commercial launch of MaterniT21 Plus, a prenatal blood test to detect fetal chromosome abnormalities. A chalk art timeline by artist Pako Pablos depicts major milestones since Sequenom launched the genetic test one year ago.

SEQUENOM INC.

CEO: Harry Hixson.

Revenue: $55.9 million in 2011; $47.5 million total revenues in 2010.

Net income or loss: Net loss of $74.2 million in 2011; Net loss of $120.8 million in 2010.

No. of local employees: 400+.

Headquarters: Torrey Pines.

Year founded: 1994.

Stock symbol and exchange: NASDAQ: SQNM.

Company description: Sequenom Inc. is a life sciences company committed to improving health care through revolutionary genetic analysis solutions.

Key factors for success: Increased field sales force; publication of MaterniT21 PLUS T18/13 clinical study results; complete AMD progression study; increase throughput and reduce COGS for the MaterniT21 PLUS LDT; complete build-out of North Carolina laboratory facility.

San Diego-based Sequenom Inc...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $129